Navigation Links
Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
Date:9/14/2012

REDMOND, Wash., Sept 14, 2012 /PRNewswire/ -- Onconome, Inc. today reported the results of studies on 431 patients based upon the blood test it has developed to determine an individual's probability of having colorectal cancer (CRC). The results of the studies have been published in the September issue of the "American Journal of Cancer Research" and demonstrate that Onconome's test is highly sensitive (93.75%) and specific (82.89%) to CRC and has a Negative Predictive Value of 99.9775% (NPV), meaning that a negative test result indicates an extremely low probability of a given patient having CRC. Onconome also reported that two additional clinical trials are now underway at three independent sites to further validate the test's efficacy as a CRC pre-screening tool.

The first of these trials (ONC04) is designed to evaluate blood samples from subjects who are 50 to 80 years old and therefore considered to be at elevated risk of CRC and who are scheduled for colonoscopy. Their samples will then be compared to their colonoscopy results to validate the test's sensitivity, specificity and NPV. The second trial (ONC05) includes patients who have already been diagnosed with CRC or pre-cancerous adenomas via colonoscopy or sigmoidoscopy and are scheduled for surgery. The endpoint of this trial is to establish the test's efficacy in detecting dangerous pre-cancerous conditions in the colon. Both trials are expected to be completed in 2013.

"It's an established fact that nearly half of adults age 50 or older have not had a colonoscopy in the past ten years and that relatively few use fecal occult blood test home kits," said Ray Cairncross, chief executive officer of Onconome. "A simple blood test which addresses these low compliance rates and provides both patients and their clinicians with an accurate assessment of an individual's risk of CRC would be an important tool in deciding whether to have a colonoscopy or sigmoidoscopy."

Onconome is a privately held clinical-stage company committed to the discovery and development of products focused on the early detection of colorectal cancer. See www.onconome.com.


'/>"/>
SOURCE Onconome, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Management Change
2. Neuralstem Announces Proposed Public Offering
3. PPCE Announces Strategic Partnership With ECLINSO AG
4. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Henry Schein Announces New $500 Million Credit Facility
8. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
9. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
10. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
11. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein ... HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... interview of two ostomy patients, standing as living proof that attitude and determination ... digestive diseases and issues that spike around the holidays. This campaign will offer ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... ... 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable ... wearable health technology on the market can deliver all that rejiva can. , “Rejiva ... about their health than the usual heart rate and steps taken”, adds Evens Augustin, ...
Breaking Medicine News(10 mins):